These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12369948)

  • 1. Intrinsic activity at adenosine A1 receptors: partial and inverse agonism.
    de Ligt RA; IJzerman AP
    Curr Pharm Des; 2002; 8(26):2333-44. PubMed ID: 12369948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors.
    Dalpiaz A; Townsend-Nicholson A; Beukers MW; Schofield PR; IJzerman AP
    Biochem Pharmacol; 1998 Dec; 56(11):1437-45. PubMed ID: 9827575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermodynamic in vitro studies as a method to investigate the pharmacodynamic behavior of adenosine A1 receptor ligands.
    Dalpiaz A; Scatturin A; Pavan B; Varani K; IJzerman AP; Andrea Borea P
    Pharm Res; 1999 Jul; 16(7):1054-8. PubMed ID: 10450930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical structure-activity studies of adenosine A1 ligands: requirements for receptor affinity.
    Dooley MJ; Kono M; Suzuki F
    Bioorg Med Chem; 1996 Jun; 4(6):923-34. PubMed ID: 8818243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding thermodynamics at A1 and A2A adenosine receptors.
    Borea PA; Dalpiaz A; Varani K; Gessi S; Gilli G
    Life Sci; 1996; 59(17):1373-88. PubMed ID: 8890916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors.
    Roelen H; Veldman N; Spek AL; von Frijtag Drabbe Künzel J; Mathôt RA; IJzerman AP
    J Med Chem; 1996 Mar; 39(7):1463-71. PubMed ID: 8691477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicinal chemistry of adenosine A1 receptor ligands.
    Soudijn W; van Wijngaarden I; IJzerman AP
    Curr Top Med Chem; 2003; 3(4):355-67. PubMed ID: 12570755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A1 adenosine receptors and their ligands: overview and recent developments.
    Müller CE
    Farmaco; 2001; 56(1-2):77-80. PubMed ID: 11347971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor.
    IJzerman AP; van der Wenden EM; van Galen PJ; Jacobson KA
    Eur J Pharmacol; 1994 Jun; 268(1):95-104. PubMed ID: 7925617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modeling the human A1 adenosine receptor and study of the mechanisms of its selective ligand binding.
    Ivanov AA; Baskin II; Palyulin VA; Zefirov NS
    Dokl Biochem Biophys; 2002; 386():271-4. PubMed ID: 12469507
    [No Abstract]   [Full Text] [Related]  

  • 11. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes.
    Link AA; Kino T; Worth JA; McGuire JL; Crane ML; Chrousos GP; Wilder RL; Elenkov IJ
    J Immunol; 2000 Jan; 164(1):436-42. PubMed ID: 10605040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of saponin on the binding and functional properties of the human adenosine A1 receptor.
    Cohen FR; Lazareno S; Birdsall NJ
    Br J Pharmacol; 1996 Apr; 117(7):1521-9. PubMed ID: 8730749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5'-O-alkyl ethers of N,2-substituted adenosine derivatives: partial agonists for the adenosine A1 and A3 receptors.
    van Tilburg EW; van der Klein PA; von Frijtag Drabbe Künzel J; de Groote M; Stannek C; Lorenzen A; IJzerman AP
    J Med Chem; 2001 Aug; 44(18):2966-75. PubMed ID: 11520205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in adenosine receptor ligands and their potential as novel drugs.
    Müller CE; Jacobson KA
    Biochim Biophys Acta; 2011 May; 1808(5):1290-308. PubMed ID: 21185259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety issues of compounds acting on adenosinergic signalling.
    Schmidt J; Ferk P
    J Pharm Pharmacol; 2017 Jul; 69(7):790-806. PubMed ID: 28397249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine receptor ligands-recent developments part I. Agonists.
    Muller CE
    Curr Med Chem; 2000 Dec; 7(12):1269-88. PubMed ID: 11032971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3D model of the human A1 adenosine receptor. An evaluation of the binding free-energy with ligands.
    Bianucci AM; Bigi MU; Biagi G; Giorgi I; Livi O; Scartoni V
    Drug Des Discov; 1998 May; 15(3):149-56. PubMed ID: 9689498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.
    Jespers W; Schiedel AC; Heitman LH; Cooke RM; Kleene L; van Westen GJP; Gloriam DE; Müller CE; Sotelo E; Gutiérrez-de-Terán H
    Trends Pharmacol Sci; 2018 Jan; 39(1):75-89. PubMed ID: 29203139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cysteine residues of rat A2a adenosine receptors in agonist binding.
    Mazzoni MR; Giusti L; Rossi E; Taddei S; Lucacchini A
    Biochim Biophys Acta; 1997 Feb; 1324(1):159-70. PubMed ID: 9059509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands.
    Tintori C; Manetti F; Botta M
    Curr Top Med Chem; 2010; 10(10):1019-35. PubMed ID: 20370655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.